{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:56:07Z","timestamp":1790826967741,"version":"4.1.0"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In this review, the authors summarized the latest developments in costimulatory blockade to prevent rejection after solid organ transplantation (SOT) and discussed possibilities for future research and the need for therapeutic drug monitoring (TDM) of these agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Studies about costimulatory blockers in SOT in humans or animal transplant models in the past decade (2014\u20132024) were systematically reviewed in PubMed, European Union clinical trials (EudraCT), and ClinicalTrials.gov.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seventy-five registered clinical trials and 58 published articles were found on costimulation blockade of the CD28-CD80\/86, CD40-CD40L, and OX40-OX40L pathways. Belatacept, an antagonist of the CD28-CD80\/86 pathway, is the only approved costimulatory agent in SOT, hence accounting for most of the research. Other identified costimulatory blocking agents included abatacept and CD28 antagonists tegoprubart, dazodalibep, and TNX-1500. Although tegoprubart was unsuccessful in pancreas transplantation in nonhuman primates, trials in human kidney transplantation are underway. Dazodalibep trials faced recruitment challenges. TNX-1500 was unsuccessful in animal studies and is currently not pursued in humans. After discontinuation of iscalimab (CD40-CD154 pathway antagonist) in SOT, the alternatives, bleselumab and KPL404, showed promising results in kidney transplantation and cardiac xenotransplantation. Studies on secondary costimulatory pathway antagonists, such as OX40-OX40L, have only used animal models. Despite the low interindividual variability in pharmacokinetics (PK) in all studied agents, TDM could be useful for optimizing dosing in PK\/pharmacodynamic (PD) studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The routine use of costimulation blockade in SOT is hindered by problems in efficacy compared with the standard of care. Costimulatory inhibitors could be combined in a calcineurin inhibitor-free regimen. Future PK\/pharmacodynamic studies in costimulatory agents and personalized medicine could warrant TDM of these agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001275","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T16:00:47Z","timestamp":1732118447000},"page":"64-76","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["New Developments and Therapeutic Drug Monitoring Options in Costimulatory Blockade in Solid Organ Transplantation: A Systematic Critical Review"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-1154","authenticated-orcid":false,"given":"Gretchen N.","family":"de Graav","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Reinier de Graaf Gasthuis, Delft, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwasin","family":"Udomkarnjananun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla C.","family":"Baan","sequence":"additional","affiliation":[{"name":"Transplant Laboratory & Research Center, Erasmus Medical Center, Rotterdam, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies E. J.","family":"Reinders","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke I.","family":"Roodnat","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C. M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Transplantation, Erasmus Medical Center, University Medical Center, Rotterdam, the Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1007\/s10620-023-08012-1","article-title":"Survival benefit of solid-organ transplantation: 10-year update","volume":"68","author":"Ferreira","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"e14320","DOI":"10.1111\/ctr.14320","article-title":"Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transpl"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.ekir.2023.08.037","article-title":"Costimulatory blockade and solid organ transplantation: the past, present, and future","volume":"8","author":"Kitchens","year":"2023","journal-title":"Kidney Int Rep"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-019-01226-6","article-title":"Costimulation blockade in kidney transplant recipients","volume":"80","author":"van der Zwan","year":"2020","journal-title":"Drugs"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"R7-20250108","first-page":"58","article-title":"Arterial stiffness in kidney transplantation: a single center case-control study comparing belatacept versus calcineurin inhibitor immunosuppressive based regimen","volume":"35","author":"Melilli","year":"2015","journal-title":"Nefrologia"},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am J Transpl"},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"e13225","DOI":"10.1111\/ctr.13225","article-title":"Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT","volume":"32","author":"Florman","year":"2018","journal-title":"Clin Transpl"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/ajt.13886","article-title":"Efficacy and safety outcomes of extended criteria donor kidneys by subtype: subgroup analysis of BENEFIT-EXT at 7 years after transplant","volume":"17","author":"Florman","year":"2017","journal-title":"Am J Transpl"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2215\/CJN.0000000000000411","article-title":"Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients","volume":"19","author":"Divard","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor\u2013 to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"1096881","DOI":"10.3389\/fimmu.2022.1096881","article-title":"Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients","volume":"13","author":"Tawhari","year":"2022","journal-title":"Front Immunol"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1097\/TP.0000000000001755","article-title":"A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation","volume":"101","author":"de Graav","year":"2017","journal-title":"Transplantation"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1111\/ajt.14377","article-title":"Lessons learned: early termination of a randomized trial of calcineurin inhibitor and corticosteroid avoidance using belatacept","volume":"17","author":"Newell","year":"2017","journal-title":"Am J Transpl"},{"key":"R16-20250108","first-page":"212","article-title":"Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant","volume":"12","author":"Bassil","year":"2014","journal-title":"Exp Clin Transpl"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Pestana","year":"2012","journal-title":"Am J Transpl"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, A randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transpl"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/ajt.12459","article-title":"Long-term exposure to belatacept in recipients of extended criteria donor kidneys","volume":"13","author":"Charpentier","year":"2013","journal-title":"Am J Transpl"},{"key":"R20-20250108","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.16170","article-title":"The potential for therapeutic drug monitoring of belatacept and other biologicals in solid organ transplantation","author":"Bergan","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/FTD.0000000000000179","article-title":"Therapeutic drug monitoring of belatacept in kidney transplantation","volume":"37","author":"de Graav","year":"2015","journal-title":"Ther Drug Monit"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bcp.13097","article-title":"Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator","volume":"83","author":"Williams","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"e13531","DOI":"10.1111\/ctr.13531","article-title":"Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts","volume":"33","author":"Sparkes","year":"2019","journal-title":"Clin Transpl"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2215\/CJN.13100820","article-title":"Belatacept for simultaneous calcineurin inhibitor and chronic corticosteroid immunosuppression avoidance: two-year results of a prospective, randomized multicenter trial","volume":"16","author":"Kaufman","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1111\/ajt.16152","article-title":"Avoidance of CNI and steroids using belatacept\u2014results of the clinical trials in organ transplantation 16 trial","volume":"20","author":"Mannon","year":"2020","journal-title":"Am J Transpl"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"e12930","DOI":"10.1111\/ctr.12930","article-title":"Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients","volume":"31","author":"Wojciechowski","year":"2017","journal-title":"Clin Transpl"},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","article-title":"Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial","volume":"69","author":"Griny\u00f3","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/ajt.14721","article-title":"De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies","volume":"18","author":"Bray","year":"2018","journal-title":"Am J Transpl"},{"key":"R36-20250108","article-title":"Comparison of de novo IgM and IgG anti-HLA DSA between belatacept and calcineurin treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts","author":"EM","year":"2018","journal-title":"Am J Transpl"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transpl"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1111\/ajt.17028","article-title":"A pilot randomized controlled trial of de novo belatacept-based immunosuppression following anti-thymocyte globulin induction in lung transplantation","volume":"22","author":"Huang","year":"2022","journal-title":"Am J Transpl"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/ajt.15817","article-title":"Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: results of a prospective, randomized clinical trial","volume":"20","author":"Stock","year":"2020","journal-title":"Am J Transpl"},{"key":"R41-20250108","article-title":"Belatacept conversion in proteinuric kidney transplant recipients: effects in a prospective trial and a retrospective cohort","volume":"22","author":"Efe","year":"2022","journal-title":"Am J Transpl"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1097\/TP.0000000000003852","article-title":"Belatacept in kidney transplant recipients with failed allografts for the prevention of humoral sensitization: a pilot randomized controlled trial","volume":"105","author":"Badell","year":"2021","journal-title":"Transplantation"},{"issue":"suppl 7","key":"R51-20250108","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1399-0012.16.s7.7.x","article-title":"Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent","volume":"16","author":"Cotterell","year":"2002","journal-title":"Clin Transpl"},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/MOT.0000000000000206","article-title":"Organ-specific differences in achieving tolerance","volume":"20","author":"Madariaga","year":"2015","journal-title":"Curr Opin Organ Transpl"},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ctr.12483","article-title":"Belatacept treatment for two yr after liver transplantation is not associated with operational tolerance","volume":"29","author":"Schwarz","year":"2015","journal-title":"Clin Transpl"},{"key":"R54-20250108","first-page":"777","article-title":"A pilot randomized controlled trial of de novo belatacept-based immunosuppression after lung transplantation","volume":"108","author":"Huang","year":"2024","journal-title":"Transplantation"},{"key":"R58-20250108","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1111\/ajt.16538","article-title":"Every 2-month belatacept maintenance therapy in kidney transplant recipients greater than 1-year posttransplant: a randomized, noninferiority trial","volume":"21","author":"Badell","year":"2021","journal-title":"Am J Transpl"},{"key":"R59-20250108","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1111\/ajt.14452","article-title":"Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly","volume":"17","author":"Vincenti","year":"2017","journal-title":"Am J Transpl"},{"key":"R60-20250108","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/ajt.15236","article-title":"Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients","volume":"19","author":"Moudgil","year":"2019","journal-title":"Am J Transpl"},{"key":"R62-20250108","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3390\/biomedicines11112955","article-title":"A validated LC-MS\/MS method for performing belatacept drug monitoring in renal transplantation","volume":"11","author":"Chhun","year":"2023","journal-title":"Biomedicines"},{"key":"R63-20250108","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transpl"},{"key":"R64-20250108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/FTD.0000000000000580","article-title":"A fully automated method for the determination of serum belatacept and its application in a pharmacokinetic investigation in renal transplant recipients","volume":"41","author":"Klaasen","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R65-20250108","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/ajt.17005","article-title":"CD86 occupancy in belatacept-treated kidney transplant patients is not associated with clinical and infectious outcomes","volume":"22","author":"de Nattes","year":"2022","journal-title":"Am J Transpl"},{"key":"R73-20250108","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.4049\/jimmunol.159.11.5187","article-title":"Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation","volume":"159","author":"Levisetti","year":"1997","journal-title":"J Immunol"},{"key":"R74-20250108","doi-asserted-by":"crossref","first-page":"8789","DOI":"10.1073\/pnas.94.16.8789","article-title":"CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates","volume":"94","author":"Kirk","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R66-20250108","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/TP.0000000000001268","article-title":"Belatacept: a game changer?","volume":"100","author":"Van Gelder","year":"2016","journal-title":"Transplantation"},{"key":"R67-20250108","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/ajt.15319","article-title":"Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation","volume":"19","author":"Badell","year":"2019","journal-title":"Am J Transpl"},{"key":"R68-20250108","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10681","article-title":"Abatacept rescue therapy in kidney transplant recipients: a case series of five patients","volume":"35","author":"Uro-Coste","year":"2022","journal-title":"Transpl Int"},{"key":"R76-20250108","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.4049\/jimmunol.1601538","article-title":"First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28","volume":"197","author":"Poirier","year":"2016","journal-title":"J Immunol"},{"key":"R77-20250108","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ajt.12964","article-title":"FR104, an antagonist anti-CD28 monovalent fab\u2019 antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft","volume":"15","author":"Poirier","year":"2015","journal-title":"Am J Transpl"},{"key":"R78-20250108","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1097\/01.tp.0000698484.85894.27","article-title":"Carfilzomib and lulizumab-based desensitization prolongs allograft survival in sensitized non-human primates kidney transplantation model","volume":"104","author":"Schroder","year":"2020","journal-title":"Transplantation"},{"key":"R79-20250108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.kint.2020.08.020","article-title":"Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model","volume":"99","author":"Schroder","year":"2021","journal-title":"Kidney Int"},{"key":"R83-20250108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jcph.791","article-title":"Pharmacokinetic, pharmacodynamic, and safety profile of a novel anti-CD28 domain antibody antagonist in healthy subjects","volume":"57","author":"Shi","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R84-20250108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cei.12152","article-title":"Activation-induced CD137 is a fast assay for identification and multi-parameter flow cytometric analysis of alloreactive T cells","volume":"174","author":"Litjens","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"R85-20250108","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1160\/TH04-12-0774","article-title":"The role of CD40 in CD40L- and antibody-mediated platelet activation","volume":"93","author":"Langer","year":"2005","journal-title":"Thromb Haemost"},{"key":"R86-20250108","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2010-01-261206","article-title":"Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis","volume":"116","author":"Lievens","year":"2010","journal-title":"Blood"},{"key":"R87-20250108","doi-asserted-by":"crossref","first-page":"22342","DOI":"10.3390\/ijms151222342","article-title":"The signaling role of cd40 ligand in platelet biology and in platelet component transfusion","volume":"15","author":"Aloui","year":"2014","journal-title":"Int J Mol Sci"},{"key":"R88-20250108","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice","volume":"185","author":"Robles-Carrillo","year":"2010","journal-title":"J Immunol"},{"key":"R90-20250108","doi-asserted-by":"crossref","first-page":"e003317","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz","year":"2023","journal-title":"RMD Open"},{"key":"R91-20250108","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00007890-200111150-00001","article-title":"Treatment with the humanized CD154-specific monoclonal antibody, hu5c8, prevents acute rejection of primary skin allografts in nonhuman primates","volume":"72","author":"Elster","year":"2001","journal-title":"Transplantation"},{"key":"R92-20250108","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1034\/j.1600-6143.2002.20603.x","article-title":"Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice","volume":"2","author":"Valujskikh","year":"2002","journal-title":"Am J Transpl"},{"key":"R93-20250108","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/01.TP.0000110291.29370.C0","article-title":"Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates","volume":"77","author":"Koyama","year":"2004","journal-title":"Transplantation"},{"key":"R94-20250108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/72162","article-title":"Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand","volume":"6","author":"Kawai","year":"2000","journal-title":"Nat Med"},{"key":"R97-20250108","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.ajt.2023.03.025","article-title":"TNX-1500, a crystallizable fragment\u2013modified anti-CD154 antibody, prolongs nonhuman primate cardiac allograft survival","volume":"23","author":"Miura","year":"2023","journal-title":"Am J Transpl"},{"key":"R98-20250108","article-title":"AT-1501, a novel and clinically applicable CD40L specific monoclonal antibody, promotes islet allograft survival in nonhuman primates [abstract]","volume":"21","author":"Berman","year":"2021","journal-title":"Am J Transpl"},{"issue":"711","key":"R99-20250108","doi-asserted-by":"crossref","first-page":"eadf6376","DOI":"10.1126\/scitranslmed.adf6376","article-title":"The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates","volume":"15","author":"Anwar","year":"2023","journal-title":"Sci Transl Med"},{"key":"R105-20250108","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/ndt\/gfw397","article-title":"IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy","volume":"33","author":"Kuo","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"R106-20250108","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1172\/JCI7014","article-title":"The soluble CD40 ligand sCD154 in systemic lupus erythematosus","volume":"104","author":"Kato","year":"1999","journal-title":"J Clin Invest"},{"key":"R107-20250108","doi-asserted-by":"crossref","first-page":"e0188045","DOI":"10.1371\/journal.pone.0188045","article-title":"Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS","volume":"12","author":"Doublier","year":"2017","journal-title":"PLoS One"},{"key":"R108-20250108","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1097\/TP.0000000000004469","article-title":"CD40-CD40L blockade: update on novel investigational therapeutics for transplantation","volume":"107","author":"Singh","year":"2023","journal-title":"Transplantation"},{"key":"R109-20250108","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.TP.0000440951.29757.bd","article-title":"Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted cynomolgus monkeys","volume":"97","author":"Ma","year":"2014","journal-title":"Transplantation"},{"key":"R110-20250108","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ajt.15560","article-title":"A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation","volume":"20","author":"Vincenti","year":"2020","journal-title":"Am J Transpl"},{"key":"R111-20250108","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ajt.15661","article-title":"First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody","volume":"20","author":"Espi\u00e9","year":"2020","journal-title":"Am J Transpl"},{"key":"R112-20250108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/ajt.15591","article-title":"Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study","volume":"20","author":"Harland","year":"2020","journal-title":"Am J Transpl"},{"key":"R113-20250108","first-page":"1782","article-title":"Efficacy and safety of bleselumab in preventing the recurrence of primary focal segmental glomerulosclerosis in kidney transplant recipients: a phase 2a, randomized, multicenter study","volume":"108","author":"Shoji","year":"2024","journal-title":"Transplantation"},{"key":"R122-20250108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically modified porcine-to-human cardiac xenotransplantation","volume":"387","author":"Griffith","year":"2022","journal-title":"N Engl J Med"},{"key":"R123-20250108","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2567.2003.01716.x","article-title":"Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients","volume":"110","author":"Contin","year":"2003","journal-title":"Immunology"},{"key":"R124-20250108","doi-asserted-by":"crossref","first-page":"670637","DOI":"10.3389\/fimmu.2021.670637","article-title":"The OX40\/OX40L axis regulates t follicular helper cell differentiation: implications for autoimmune diseases","volume":"12","author":"Fu","year":"2021","journal-title":"Front Immunol"},{"key":"R125-20250108","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/cpt.2539","article-title":"OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-of-pharmacology for KY1005","volume":"111","author":"Saghari","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R126-20250108","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biomedicines11051303","article-title":"Novel therapeutic targets for the treatment of atopic dermatitis","volume":"11","author":"Tsuji","year":"2023","journal-title":"Biomedicines"},{"key":"R127-20250108","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3390\/pharmaceutics14122753","article-title":"OX40-OX40L inhibition for the treatment of atopic dermatitis\u2014focus on rocatinlimab and amlitelimab","volume":"14","author":"L\u00e9","year":"2022","journal-title":"Pharmaceutics"},{"key":"R128-20250108","doi-asserted-by":"crossref","first-page":"e90317","DOI":"10.1172\/jci.insight.90317","article-title":"Interruption of OX40L signaling prevents costimulation blockade\u2013resistant allograft rejection","volume":"2","author":"Kitchens","year":"2017","journal-title":"JCI Insight"},{"key":"R129-20250108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21037\/atm.2019.12.146","article-title":"Blockade of OX40\/OX40L pathway combined with ethylene-carbodiimide-fixed donor splenocytes induces donor-specific allograft tolerance in presensitized recipients","volume":"8","author":"Lai","year":"2020","journal-title":"Ann Transl Med"},{"key":"R130-20250108","first-page":"2686","article-title":"Blockade of the OX40\/OX40L pathway and induction of PD-L1 synergistically protects mouse islet allografts from rejection","volume":"127","author":"Li","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R131-20250108","doi-asserted-by":"crossref","first-page":"107663","DOI":"10.1016\/j.intimp.2021.107663","article-title":"Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs","volume":"97","author":"Wang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R132-20250108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2015.01.001","article-title":"Anti-OX40L monoclonal antibody prolongs secondary heart allograft survival based on CD40\/CD40L and LFA-1\/ICAM-1 blockade","volume":"32","author":"Dai","year":"2015","journal-title":"Transpl Immunol"},{"key":"R133-20250108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2015.08.005","article-title":"An immunotherapeutic strategy for prolonging graft survival in mice","volume":"33","author":"Wang","year":"2015","journal-title":"Transpl Immunol"},{"key":"R134-20250108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3892\/ijmm.2016.2808","article-title":"Immunomodulatory effects of OX40Ig gene-modified adipose tissue-derived mesenchymal stem cells on rat kidney transplantation","volume":"39","author":"Liu","year":"2017","journal-title":"Int J Mol Med"},{"key":"R135-20250108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10557-013-6502-9","article-title":"Memory T cells mediate cardiac allograft vasculopathy and are inactivated by anti-OX40L monoclonal antibody","volume":"28","author":"Wang","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"R136-20250108","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/imr.12523","article-title":"Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy","volume":"276","author":"Kean","year":"2017","journal-title":"Immunol Rev"},{"key":"R137-20250108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"R138-20250108","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1: PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"R139-20250108","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat Immunol"},{"key":"R140-20250108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T10:01:47Z","timestamp":1736330507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001275","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"2024-07-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}